Abstract
The COVID-19 pandemic raises the need for diverse diagnostic approaches to rapidly detect different stages of viral infection. The flexible and quantitative nature of single-molecule imaging technology renders it optimal for development of new diagnostic tools. Here we present a proof-of-concept for a single-molecule based, enzyme-free assay for detection of SARS-CoV-2. The unified platform we developed allows direct detection of the viral genetic material from patients’ samples, as well as their immune response consisting of IgG and IgM antibodies. Thus, it establishes a platform for diagnostics of COVID-19, which could also be adjusted to diagnose additional pathogens.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
N.F. is supported by the Israel Cancer Research Fund. E.S. is an incumbent of the Lisa and Jeffrey Aronin Family Career Development chair. This research was supported by internal grants of the Weizmann Institute of Science, as well as Quinquin Foundation, The Benoziyo Fund for the Advancement of Science, The Sagol Institute for Longevity Research and The Willner Family Center for Vascular Biology
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was granted exemption from The Galilee Medical Center (GMC) Institutional Review Boards (IRB) approval for utilizing discarded pooled RNA samples, anonymized and de-identified, for single-molecule detection of SARS-CoV-2 RNA with a multiplex approach. Research with the COVID-19 serum samples has been approved by the Weizmann Institute of Science institutional review board (#1030-4 and #1012-1). Use of plasma samples by NIH investigators was approved under conditions set out in an Emergency Use Simple Letter Agreement signed by The Sheba Fund for Health Services & Research and by our local ethical board (protocol 7160-20-SMC). All samples were coded and de-identified as specified in the informed consent and the NIH investigator attestation addressing the protection of human subjects and approved by the NIH Office of Human Subjects Research Protections (OHSRP). NIH research teams and the Sheba medical center teams had no access to identifiers or ability to reidentify subjects at any point. Research of serum samples from healthy individuals (no prior COVID-19 infection) has been approved by the Weizmann Institute of Science institutional review board (IRB: 1097-2)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is available in the main text or the supplementary materials
